We are live on ! Find out more
HCM

Highbridge Capital Management Portfolio holdings

AUM $3.09B
1-Year Est. Return 31.19%
This Fund
S&P 500
This Quarter Est. Return
+0.8%
1 Year Est. Return
+31.19%
3 Year Est. Return
+54.53%
5 Year Est. Return
+78.37%
10 Year Est. Return
+191.39%
AUM
$6.03B
AUM Growth
-$525M
Cap. Flow
-$1.36B
Cap. Flow %
-22.63%
Top 10 Hldgs %
9.74%
Holding
2,156
New
706
Increased
305
Reduced
357
Closed
728

Sector Composition

Rank Sector Weight
1 Healthcare 7.09%
2 Technology 7.04%
3 Consumer Discretionary 6.57%
4 Industrials 5.49%
5 Financials 4.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ANTH
1351
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$99K ﹤0.01%
+3,429
New +$93K
MTUS icon
1352
Metallus
MTUS
$851M
$96K ﹤0.01%
+10,551
New +$77.2K
NVAX icon
1353
CALL
Novavax
NVAX
$1.22B
$89K ﹤0.01%
865
+150
+21% +$16.1K
IBRX icon
1354
ImmunityBio
IBRX
$7.49B
$87K ﹤0.01%
+10,605
New +$99.9K
SSRI
1355
CALL
DELISTED
Silver Standard Resources
SSRI
$83K ﹤0.01%
+14,900
New +$78.7K
MTG icon
1356
MGIC Investment
MTG
$6.27B
$82K ﹤0.01%
+10,662
New +$76.4K
TRTLW
1357
DELISTED
Terrapin 3 Acquisition Corporation
TRTLW
$75K ﹤0.01%
+250,000
New +$76.4K
SGI
1358
PUT
DELISTED
Silicon Graphics Intl.
SGI
$75K ﹤0.01%
+10,600
New +$64.7K
SVU
1359
PUT
DELISTED
SUPERVALU Inc.
SVU
$73K ﹤0.01%
1,800
-3,657
-67% -$130K
KRO icon
1360
KRONOS Worldwide
KRO
$708M
$71K ﹤0.01%
+12,390
New +$64.6K
TVRD
1361
Tvardi Therapeutics
TVRD
$19M
$69K ﹤0.01%
307
-745
-71% -$223K
CZZ
1362
DELISTED
Cosan Limited
CZZ
$67K ﹤0.01%
+13,800
New +$48.2K
MXWL
1363
PUT
DELISTED
Maxwell Technologies Inc
MXWL
$65K ﹤0.01%
10,900
-24,600
-69% -$151K
EMKR
1364
DELISTED
Emcore Corp
EMKR
$65K ﹤0.01%
1,306
-4,463
-77% -$243K
MWW
1365
DELISTED
Monster Worldwide Inc
MWW
$64K ﹤0.01%
+19,500
New +$75.8K
SVU
1366
DELISTED
SUPERVALU Inc.
SVU
$63K ﹤0.01%
1,551
-173,064
-99% -$6.16M
MXWL
1367
CALL
DELISTED
Maxwell Technologies Inc
MXWL
$61K ﹤0.01%
10,300
-11,000
-52% -$67.4K
CYHHZ
1368
DELISTED
Community Health Systems, Inc. Series A Contingent Value Rights
CYHHZ
$60K ﹤0.01%
10,043,260
BCRX icon
1369
BioCryst Pharmaceuticals
BCRX
$2.24B
$58K ﹤0.01%
+20,533
New +$91K
ARRY
1370
DELISTED
Array Biopharma Inc
ARRY
$58K ﹤0.01%
19,681
-362,637
-95% -$1.09M
ALTO icon
1371
PUT
Alto Ingredients
ALTO
$377M
$57K ﹤0.01%
12,200
-150,100
-92% -$589K
NPKI
1372
NPK International
NPKI
$1.12B
$53K ﹤0.01%
+12,210
New +$52.2K
ZIXI
1373
DELISTED
Zix Corporation
ZIXI
$52K ﹤0.01%
+13,389
New +$55.9K
FBP icon
1374
First Bancorp
FBP
$4.43B
$31K ﹤0.01%
10,907
-206,153
-95% -$549K
AA icon
1375
Alcoa
AA
$11.8B
-8,921
Closed -$212K

Similar funds

Highbridge Capital Management's Q1 2016 Portfolio in Review

As of Q1 2016, Highbridge Capital Management held 2,156 positions worth $6.03B, down 8% from $6.55B the previous quarter. Its ten largest holdings account for 9.7% of the portfolio.

Highbridge Capital Management withdrew a net $1.36B in Q1 2016, closing 728 positions and reducing 357 holdings. Its most notable exit was PRECISION CASTPARTS CORP, an estimated $43M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 7.1% of assets, down from 11% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Highbridge Capital Management opened a new position in Express Scripts Holding Company worth $43.6M.

  • Highbridge Capital Management's largest Q1 2016 buy was Express Scripts Holding Company: 634,478 shares worth $43.6M.
  • Highbridge Capital Management added most to Southwestern Energy Company in Q1 2016, an estimated $34.6M increase.
  • Highbridge Capital Management's biggest Q1 2016 reduction was Gilead Sciences, cutting an estimated $60.7M.
  • Highbridge Capital Management fully exited PRECISION CASTPARTS CORP in Q1 2016, selling an estimated $43M.
  • Highbridge Capital Management's ten largest holdings make up 9.7% of its $6.03B portfolio in Q1 2016.
  • Highbridge Capital Management opened 706 new positions and closed 728 in Q1 2016.
  • Highbridge Capital Management's portfolio value fell 8% quarter-over-quarter to $6.03B.

Based on Highbridge Capital Management's 13F filing for Q1 2016, filed 16 May 2016.